Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia

Müller, Matthias J.; Регенбоген, Б.; Härtter, Sebastian; Eich, F.X.; Hiemke, Christoph

doi:10.1016/j.jpsychires.2005.10.003

Cited by 48 publications

(50 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the relationship between concentration and effectiveness, only 2 studies compared plasma levels of amisulpride between responder and nonresponder groups . Meisenzahl et al reported no significant differences in the plasma concentrations between responder and nonresponder groups (172.1 ± 95.8 [ n = 14] vs. 224.7 ± 233.7 [ n = 15], respectively, P = .45) with similar doses .…”

Section: Resultsmentioning

confidence: 99%

“…The Arbeitsgemeinschaftfür Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) consensus guidelines consider amisulpride therapeutic drug monitoring (TDM) as strongly recommended (level 1), while also suggesting that the therapeutic reference range for amisulpride is 100–320 ng/mL, with a laboratory alert level of 640 ng/mL . The suggested range was supported by only 1 study with 378 patients administered once daily, which considered both clinical nonresponse and extrapyramidal side effect (EPS) by receiver operating characteristic analysis . Amisulpride can be administered once daily at oral doses up to 400 mg, higher doses should be administered twice‐daily (BID).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and combined meta‐analysis of concentration of oral amisulpride

Lü

Shang

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims Amisulpride, a first‐line schizophrenia treatment, has shown large interindividual variability in plasma/serum levels, often outside the reference range (100–320 ng/mL). This study aims to clarify the impact of dose, sex, age and related factors for the interpatient variability in amisulpride plasma/serum concentration. Methods Both English and Chinese databases were searched from their inception to May 16, 2019, using the terms: amisulpride and (plasma OR serum OR blood OR “drug monitoring” OR concentration). Studies reporting concentrations and either a dose, associated factor, clinical outcome or side effect were included. Results Fourteen studies with 1628 participants were eventually included. Eligible articles yielded data on drug concentration and dose, averaging 333.9 (95% confidence interval [CI]: 294.5–373.3) ng/mL and 636.2 (95% CI: 549.7–722.6) mg/d, respectively. The calculated mean concentration‐to‐dose (C/D) ratio was 0.60 (95% CI: 0.52–0.67) (ng/mL)/mg. Subgroup analysis suggested that female patients on combined lithium‐amisulpride have higher concentration levels and C/D ratios. Age was slight positive associated with C/D ratio while not for plasma level. Smoker patients have high concentration level than nonsmoking patients but not for C/D. Responsive and nonresponsive groups did not differ in concentration and C/D. Conclusion Pooled concentration levels of amisulpride were higher than recommended with wide individual variation, especially in older patients, female patients and patients taking amisulpride combined with lithium. The specific therapeutic reference range for amisulpride may require reconstruction, which should consider the influence of age, sex, kidney function, drug–drug interactions, different dose regimens and sampling times in future study.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A systematic review and combined meta‐analysis of concentration of oral amisulpride

Lü

Shang

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Therefore, our experiments have been designed to investigate the role of beta-glucan as the antioxidant in the defence of plasma lipid against oxidative damages (by measurement of well-known marker such as thiobarbituric acid reactive substances (TBARS) level) caused by first generation antipsychotic -haloperidol 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one and the second generation antipsychotic -amisulpride (4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsufonyl-2-methoxy-benzamide) in vitro. The tested concentrations of antipsychotic drugs correspond to doses used for treatment of acute episode of schizophrenia [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol

Dietrich‐Muszalska

Olas

Kontek

et al. 2011

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

“…Therefore, our experiments have been designed to investigate the role of other well-studied polyphenol found in green tea-epicatechin (2 R, 3 S)-2 2 (3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol) in the defence of plasma lipid against oxidative damages (by measurement of well-known marker such as thiobarbituric acid reactive substances (TBARS) level) caused by first generation antipsychotic (FGA)-haloperidol 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one and probably second generation antipsychotic (SGA)-amisulpride (4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsufonyl-2-methoxy-benzamide) in vitro. The tested concentrations of antipsychotic drugs (haloperidol-20 ng/ml; amisulpride-578 ng/ml) correspond to doses used for treatment of acute episode of schizophrenia [5,24]. In these studies we also compared the action of epicatechin with the effects of other well-known antioxidants-resveratrol and quercetin.…”

Section: Introductionmentioning

confidence: 99%

Epicatechin Inhibits Human Plasma Lipid Peroxidation Caused by Haloperidol In Vitro

et al. 2011

View full text Add to dashboard Cite

Epicatechin belongs to flavonoids protecting cells against oxidative/nitrative stress. Oxidative/nitrative stress observed in schizophrenia may be caused partially by the treatment of patients with various antipsychotics. The aim of our study was to establish the effects of epicatechin and antipsychotics action (the first generation antipsychotic (FGA)--haloperidol and the second generation antipsychotic (SGA)--amisulpride) on peroxidation of plasma lipids in vitro. Lipid peroxidation in human plasma was measured by the level of thiobarbituric acid reactive species (TBARS). The properties of epicatechin were also compared with the action of a well characterized antioxidative commercial polyphenol-resveratrol (3,4',5-trihydroxystilbene) and quercetin (3,5,7,3',4'-pentahydroxyflavone). Amisulpride, contrary to haloperidol (after 1 and 24 h) does not significantly influence the increase of plasma TBARS level in comparison with control samples (P > 0.05). After incubation (1 and 24 h) of plasma with haloperidol in the presence of epicatechin we observed a significantly decreases the level of TBARS (P < 0.001, P < 0.001, respectively). In our other experiments, we found that epicatechin also decreased the amount of TBARS in human plasma treated with amisulpride. In conclusion, the presented results indicate that epicatechin-the major polyphenolic component of green tea reduced significantly human plasma lipid peroxidation caused by haloperidol. Moreover, epicatechin was found to be a more effective antioxidant, than the solution of pure resveratrol or quercetin.

show abstract

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia

Cited by 48 publications

References 35 publications

A systematic review and combined meta‐analysis of concentration of oral amisulpride

A systematic review and combined meta‐analysis of concentration of oral amisulpride

Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol

Epicatechin Inhibits Human Plasma Lipid Peroxidation Caused by Haloperidol In Vitro

Contact Info

Product

Resources

About